Resources from the same session
652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Presenter: Kathryn Arbour
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
Presenter: Jie Wang
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA33 - A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
Presenter: Caicun Zhou
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 652O, 653O and LBA33
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Developmental therapeutics
Resources:
Webcast
654O - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Presenter: Bob Li
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
655O - Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)
Presenter: Melissa Johnson
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Developmental therapeutics
Resources:
Webcast